related documents
- Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC) Conferences
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) Conferences
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC) Conferences
- Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model Conferences
- FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) Conferences
- Serum netrin-1 as a biomarker for colorectal cancer detection Conferences
- Tobacco retail access and tobacco cessation among head and neck cancer (HNC) survivors Conferences